2018 revenue: $1.102 billion
NuVasive’s stock (NSDQ:NUVA) jumped about 17% in value, to around $58 per share, in early February after media reports that Smith & Nephew was reportedly in talks to acquire the maker of minimally invasive spine products. NuVasive’s stock price settled down a bit in March, though, after Smith & Nephew agreed to spend $660 million to acquire Osiris Therapeutics (NSDQ:OSIR).
“NuVasive delivered strong year-over-year revenue growth of more than 7% in 2018, demonstrating the company’s ability to take share in a stable but relatively flat U.S. spine market,” CEO Chris Barry said in a February earnings press release.
“Additionally, we made significant progress at our West Carrollton manufacturing facility, exiting the year at 70% SKU rationalization,” Barry said. “Collectively, these achievements serve to advance our mission to bring disruptive technology to surgeon partners to enable better, more predictable patient outcomes.”
NuVasive recently announced the U.S. launch of its X360 system, intended for lateral single-position spine surgery.